COVID-19 Pandemic Drove Fivefold Rise in Ultra-Hypofractionated Breast Radiation Among Medicare Beneficiaries

The study documented a shift away from conventional 22-plus fraction regimens, which fell from 23.2% to 16.4%, coinciding with pandemic-driven efforts to limit healthcare visits. Average radiotherapy sessions dropped by nearly two per patient and treatment duration shortened by three days. Spending decreased by roughly $412 per case, with ultra-hypofractionated courses averaging $1,848 versus $8,820 for conventional schedules. Largest gains occurred in patients over 80 and those with high comorbidity burdens.

Prior evidence from the UK FAST trial supported five-fraction schedules years earlier, yet adoption remained gradual until COVID-era guidance aligned incentives. The pandemic compressed timelines that had previously spanned a decade for standard hypofractionation. Regional variation was pronounced, with the Northeast showing the steepest uptake, while Black patients experienced no comparable increase despite overall gains among White patients.

This pattern reveals how external shocks can override inertia in guideline implementation, yet also exposes persistent equity gaps that pre-pandemic slow diffusion masked. Policy levers such as bundled payments and visit-reduction incentives may sustain gains, but long-term tumor control and toxicity data in routine Medicare populations remain limited.

Future work must track recurrence rates beyond five years and test targeted interventions to close racial adoption disparities. Without such data, value-based claims rest on surrogate endpoints and short-term utilization metrics.